Can adding an immune booster to radiation keep lymphoma away longer?
NCT ID NCT01473628
First seen Nov 06, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This study compares radiation therapy alone versus radiation plus rituximab (a drug that helps the immune system attack cancer) for patients with early-stage (I or II) low-grade follicular lymphoma. The goal is to see if the combination keeps the cancer from progressing longer. About 81 newly diagnosed adults are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE I GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.